Ahead of the Pharmaconex 2025 Conference, Dr. Ali El-Ghamrawy, President of the Egyptian Drug Authority (EDA), held a high-level coordination meeting to discuss organizing this pharmaceutical and biotechnological exhibition. The conference is set to take place from September 1 to 3, 2025, and will gather major global stakeholders in pharmaceutical innovation, manufacturing, and regulation.
During the meeting, discussions centered on the EDA’s strategic participation in the upcoming event — including exhibition plans, panel contributions, and showcasing Egypt’s national pharmaceutical achievements. A key focus was highlighting Egypt’s growing role as a regional pharmaceutical hub, and the Authority’s expanding international engagement.
Strategic Industry Support and Global Integration
Dr. El-Ghamrawy emphasized that Pharmaconex 2025 presents an important opportunity for Egypt to demonstrate its regulatory leadership and commitment to pharmaceutical innovation on a global stage.
The EDA’s engagement at Pharmaconex is expected to include in-depth sessions on governance, market regulation, drug safety, and industry competitiveness, with a particular emphasis on local production and regional expansion. These efforts align with Egypt’s broader healthcare reform and industrial localization strategies.
Pharmaceutical Governance
Pharmaconex is recognized as the Middle East and Africa’s premier platform for pharmaceutical and biotechnological exchange. Egypt’s prominent role in the 2025 edition underscores the nation’s rising influence in regulatory excellence and pharmaceutical policy development.
Institutional Commitment To Egypt’s Pharmaceutical Future
This strategic dialogue reinforces Egypt’s national vision to become a central pharmaceutical and biotechnology innovation node in Africa and the Middle East, while contributing to global pharmaceutical discourse.
With more than 150 companies and regulatory entities expected to attend Pharmaconex 2025, Egypt’s participation is not only timely — it’s critical. The EDA aims to leverage this platform to strengthen ties with international regulators, manufacturers, and health organizations, and to attract foreign investment into Egypt’s growing pharmaceutical sector.
As Egypt’s pharmaceutical industry undergoes rapid modernization, the EDA’s forward-looking regulatory approach is expected to shape regional norms and establish Egypt as a trusted partner in global health security.
Pharmaconex 2025 marks another milestone in this journey — positioning Egypt not just as a market participant, but as a leader in pharmaceutical policy, production, and innovation.
